Managers / Q1 2026
Exeter Financial, LLC
CIK 0001752045 · 7001 N. SCOTTSDALE ROAD, SUITE 1055, SCOTTSDALE, AZ, 85253-3644 · 480 588-0830
Summary
Exeter Financial, LLC reported $245M in U.S.-listed holdings across 98 positions for Q1 2026.
Its largest position, Ishares Tr, represents 5.2% of the portfolio.
Compared with Q4 2025, the fund opened 2 new positions and exited 1.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 72.7% · $178M
- ETP · 19.8% · $49M
- Closed-End Fund · 4.8% · $12M
- Other · 2.4% · $6M
- ADR · 0.2% · $535,705
Quarter-over-Quarter Changes full breakdown →
vs Q4 2025 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| GOOGALPHABET INC | NEW | +732 | 732 | +$209,982 | $209,982 |
| ASTRAZENECA PLC | NEW | +1.0K | 1.0K | +$202,151 | $202,151 |
| NVONOVO-NORDISK A S | ADDED | +9.7K | 14.6K | +$286,647 | $535,705 |
| HRLHORMEL FOODS CORP | ADDED | +14.0K | 26.0K | +$304,496 | $589,911 |
| CLXCLOROX CO DEL | SOLD OUT | −2.1K | 0 | −$213,450 | $0 |
| NKENIKE INC | ADDED | +7.5K | 15.6K | +$307,974 | $826,194 |
| UNHUNITEDHEALTH GROUP INC | ADDED | +1.2K | 2.6K | +$246,987 | $701,664 |
| NVDANVIDIA CORPORATION | ADDED | +1.5K | 4.1K | +$223,234 | $721,278 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2026
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $245M | 98 | Apr 23, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $235M | 97 | Jan 7, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $232M | 92 | Oct 6, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $225M | 91 | Jul 16, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $223M | 90 | Apr 4, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $218M | 91 | Jan 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $226M | 93 | Oct 8, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $210M | 88 | Jul 12, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $217M | 90 | Apr 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $206M | 88 | Jan 16, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $189M | 87 | Oct 16, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $194M | 88 | Jul 27, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $200M | 88 | May 10, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $192M | 84 | Jan 24, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $172M | 88 | Oct 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $179M | 86 | Jul 20, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $184M | 84 | Apr 27, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $183M | 83 | Jan 25, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $167M | 79 | Oct 22, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $172M | 82 | Jul 30, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $159M | 78 | Apr 30, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $144M | 77 | Feb 5, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $128M | 70 | Oct 8, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $120M | 68 | Jul 21, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $106M | 66 | Apr 23, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $129M | 68 | Jan 29, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $126M | 69 | Oct 28, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $120M | 69 | Jul 26, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $116M | 68 | Apr 9, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $106M | 65 | Feb 12, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.